BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an R&D Day from 8:30am (ET) to 11:30am (ET) on Wednesday, November 7, 2018 in New York City....

SAN RAFAEL, Calif. , Nov. 1, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) will host an R&D Day from 8:30am (ET) to 11:30am (ET) on Wednesday , November 7, 2018 in New York City . BioMarin management and external experts will provide an update to the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases.

BioMarin R&D Day 2018 Agenda

Welcome and Opening Remarks

Vosoritide for Achondroplasia

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

Regulatory Policy Advances at the Food and Drug Administration

PKU Gene Therapy Data and Program update; R&D Pipeline Deep Dive

Closing Statements

Live Video Webcast Interested parties may access a live video webcast that will include audio and slides of the presentations here . A replay of the meeting will be archived on the site for at least one week.

For those who choose not to listen and view the event via webcast, dial-in information for the audio portion of the webcast can be accessed using:

USA : (913) 227-1201 USA / Canada (toll free): (866) 705-2554 Conference ID: 6342187

About BioMarin BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.

For additional information, please visit www.biomarin.com . Information on BioMarin's website is not incorporated by reference into this press release.

SOURCE BioMarin Pharmaceutical Inc.